公开(公告)号：EP4374877A3

公开(公告)日：2024-07-17

申请号：EP24161259.7

申请日：2015-09-11

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： Ohtake, Yoshihito ,  Okamoto, Naoki ,  Ono, Yoshiyuki ,  Kashiwagi, Hirotaka ,  Kimbara, Atsushi ,  Harada, Takeo ,  Hori, Nobuyuki ,  Murata, Yoshihisa ,  Tachibana, Kazutaka ,  Tanaka, Shota ,  Nomura, Kenichi ,  Ide, Mitsuaki ,  Mizuguchi, Eisaku ,  Ichida, Yasuhiro ,  Ohtomo, Shuichi ,  Horiba, Naoshi

IPC分类号： A61K31/50 ,  A61K31/19 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/503 ,  A61K31/506 ,  A61K31/537 ,  A61K31/5377 ,  A61K31/734 ,  A61K33/08 ,  A61K33/10 ,  A61K33/24 ,  A61K33/26 ,  A61K45/00 ,  A61P3/12 ,  A61P5/18 ,  A61P9/10 ,  A61P13/12 ,  A61P43/00

CPC分类号： C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  A61K45/00 ,  A61K31/19 ,  A61K31/4545 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/503 ,  A61K31/506 ,  A61K31/537 ,  A61K31/5377 ,  A61K31/734 ,  A61K33/08 ,  A61K33/10 ,  A61K33/24 ,  A61K33/26 ,  C07D401/06 ,  C07D401/12 ,  C07D237/04 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D498/08 ,  A61K33/244 ,  A61K45/06 ,  A61K31/24 ,  A61P13/12

摘要： The present invention provides a pharmaceutical composition containing, as an active ingredient, a dihydropyridazine-3,5-dione derivative or a salt thereof or a solvate of these, wherein the composition is administered in combination with a phosphorus adsorbent.

公开(公告)号：EP4397663A1

公开(公告)日：2024-07-10

申请号：EP22864569.3

申请日：2022-08-30

申请人： Japan Tobacco, Inc.

发明人： OHBA, Yusuke ,  ADACHI, Kaoru ,  NISHIMARU, Tatsuya ,  SAKURAI, Kentaro ,  OGOSHI, Yosuke ,  SATO, Shimpei

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P9/00 ,  A61P9/10 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P25/28

CPC分类号： A61K31/519 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P9/00 ,  A61P9/10 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/06 ,  A61P21/02 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P27/04 ,  A61P29/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04 ,  C07D519/00

摘要： A 6-aminopyrazolopyrimidine compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided.
A compound of Formula [IA]:

or a pharmaceutically acceptable salt thereof,
wherein a partial structure:

is a structure of the following formula:

etc.
wherein R4 is hydrogen or C1-4 alkyl, in which the alkyl may be optionally substituted with hydroxy or cyano,
Ring group CyA is a group of the following formula:

etc.
wherein R6 and R7 are, each independently, hydrogen, hydroxy, cyano, C1-6 alkyl, etc., R8 and R9 are, each independently, hydrogen, C1-4 alkyl, or C1-4 haloalkyl, R10 is hydrogen, cyano, C1-6 alkyl, etc.),
R1 is hydrogen or C1-4 alkyl,
R2A and R3A are, each independently, hydrogen, C1-6 alkyl etc., alternatively, R2A and R3A may combine together with the nitrogen atom to which they attach and the -NR2AR3A group may form a 4- to 7-membered optionally-substituted heterocycloalkyl, etc.

公开(公告)号：EP4397314A1

公开(公告)日：2024-07-10

申请号：EP24159638.6

申请日：2013-10-22

申请人： Stealth BioTherapeutics Inc. ,  Henry Ford Health Systems

发明人： WILSON, Travis D. ,  SABBAH, Hani N

IPC分类号： A61K38/00 ,  A61P9/10 ,  A61P9/00

CPC分类号： A61K38/06 ,  A61P1/02 ,  A61P25/30 ,  A61P25/32 ,  A61P29/00 ,  A61P31/12 ,  A61P43/00 ,  A61P5/14 ,  A61P7/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12

摘要： The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to increase expression of Taz1 and/or increase mK ATP activity in subjects in need thereof.

公开(公告)号：EP4392559A1

公开(公告)日：2024-07-03

申请号：EP22859731.6

申请日：2022-08-22

申请人： Northern Therapeutics Inc.

发明人： STEWART, Duncan ,  COURTMAN, David

IPC分类号： C12N15/113 ,  A61K35/12 ,  A61K38/44 ,  A61K48/00 ,  A61P9/00 ,  A61P9/10 ,  C12N9/02 ,  C12N15/10 ,  C12N15/53 ,  C12N15/85

CPC分类号： A61P9/00 ,  A61P9/10 ,  C12N15/85 ,  C12N9/0075 ,  C12Y114/13039 ,  C12N2830/00820130101 ,  C12N2830/00220130101 ,  A61K48/005 ,  A61K48/0058 ,  C12N2830/1520130101

公开(公告)号：EP4382111A1

公开(公告)日：2024-06-12

申请号：EP22386089.1

申请日：2022-12-09

申请人： The University Court Of The University of Edinburgh

发明人： Kesidou, Despoina ,  Beqqali, Abdelaziz ,  Baker, Andrew ,  Brittan, Mairi ,  Mountford, Joanne

IPC分类号： A61K35/545 ,  A61P9/00 ,  A61K35/12 ,  A61K35/44 ,  A61L27/54 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P17/02 ,  B01D15/34

CPC分类号： A61K35/12 ,  A61K35/44 ,  A61K35/545 ,  A61L27/54 ,  B01D15/34 ,  A61P9/00 ,  A61P9/10 ,  A61P17/02 ,  A61P11/00 ,  A61P9/12 ,  A61L31/16 ,  A61L2300/62620130101 ,  A61L2300/6420130101

摘要： The present disclosure relates to extracellular vesicles (EVs) (and their contents) from a pluripotent stem-cell derived endothelial cell product (ECP); as well as their isolation; uses and methods employing the EVs in therapy, such as in promoting angiogenesis and/or neovascularisation.

公开(公告)号：EP3592824B1

公开(公告)日：2024-06-12

申请号：EP18764116.2

申请日：2018-03-06

IPC分类号： C09K11/08 ,  C09K11/64 ,  C09K11/77 ,  A61K33/04 ,  A61M1/16 ,  A61P7/08 ,  A61P9/10 ,  A61P9/12

CPC分类号： A61M1/1656 ,  A61M1/1654 ,  A61K33/04 ,  A61P7/08 ,  A61P9/10 ,  A61P9/12

公开(公告)号：EP3689344B1

公开(公告)日：2024-06-05

申请号：EP19218071.9

申请日：2016-04-13

IPC分类号： A61K31/277 ,  A61K9/08 ,  A61K9/00 ,  A61P25/06 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  C07C255/42 ,  A61K47/20 ,  A61K47/18 ,  A61K47/12

CPC分类号： A61K9/08 ,  C07C255/42 ,  A61K9/0043 ,  A61K47/12 ,  A61K47/183 ,  A61K47/20 ,  A61K31/277 ,  A61P9/10 ,  A61P9/06 ,  A61P25/06

公开(公告)号：EP4374914A1

公开(公告)日：2024-05-29

申请号：EP22845958.2

申请日：2022-07-20

申请人： Kyoto University

发明人： EIRAKU, Mototsugu

IPC分类号： A61P9/10 ,  A61P27/02 ,  C12M3/00 ,  C12N5/07 ,  C12N5/0735 ,  C12N5/10 ,  A61K35/30 ,  A61L27/38 ,  A61L27/40 ,  C07K14/78

CPC分类号： A61K35/30 ,  A61L27/38 ,  A61L27/40 ,  A61P9/10 ,  A61P27/02 ,  C07K14/78 ,  C12M3/00 ,  C12N5/06 ,  C12N5/10

摘要： The present disclosure includes a method of producing a retinal tissue, comprising inducing differentiation of pluripotent stem cells into a retinal tissue on a surface of a culture substrate, wherein the culture substrate comprises a region A and a region B on the surface, the differentiation is induced is the region A, the region A has cell adhesiveness, and the region B is adjacent to at least a part of the region A and has cell adhesiveness lower than the cell adhesiveness of the region A; a retinal tissue produced by the method; and a composition comprising the retinal tissue.

公开(公告)号：EP4331607A3

公开(公告)日：2024-05-29

申请号：EP23214939.3

申请日：2016-12-01

申请人： Nippon Shinyaku Co., Ltd.

发明人： FURUTA, Shouji ,  MUKAI, Hironori

IPC分类号： A61K31/4965 ,  A61K9/16 ,  A61K9/20 ,  A61P7/02 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P11/06

CPC分类号： A61K9/1623 ,  A61K9/2018 ,  A61P9/10 ,  A61P11/00 ,  A61P7/02 ,  A61P13/12 ,  A61P11/06 ,  A61K9/1611 ,  A61K9/2059 ,  A61K31/4965 ,  A61P9/12 ,  A61K9/1652 ,  A61K9/2054 ,  A61K9/2013

摘要： A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butylo xy}-N-(methylsulfonyl)acetamide is provided.
A solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butylo xy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.

公开(公告)号：EP4342546A3

公开(公告)日：2024-05-22

申请号：EP24152348.9

申请日：2013-06-28

申请人： Amarin Pharmaceuticals Ireland Limited

发明人： SONI, Paresh

IPC分类号： A61K31/232 ,  A61K31/397 ,  A61K45/06 ,  A61P9/10 ,  A61P9/00 ,  A61P3/04 ,  A61P3/06 ,  A61P9/04 ,  A61P9/06 ,  A61P43/00

CPC分类号： A61K31/397 ,  A61K31/232 ,  A61P3/04 ,  A61P3/06 ,  A61P43/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10

摘要： In various embodiments, the present invention provides pharmaceutical compositions for use in methods of reducing a risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 4 g of eicosapentaenoic acid ethyl ester per day.